Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia

Published:2020-09-02 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Märklin Melanie,Fuchs Alexander R.,Tandler Claudia,Heitmann Jonas S.,Salih Helmut R.,Kauer Joseph,Quintanilla-Martinez Leticia,Wirths Stefan,Kopp Hans-Georg,Müller Martin R.

Funder

Deutsche Krebshilfe

Deutsche Forschungsgemeinschaft

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;New Engl J Med.,2014

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet.,2010

3. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;New Engl J Med.,2013

4. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;New Engl J Med.,2014

5. Ibrutinib and venetoclax for first-line treatment of CLL;Jain;N Engl J Med.,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-Wide Methylation Profiling of Peripheral T–Cell Lymphomas Identifies TRIP13 as a Critical Driver of Tumor Proliferation and Survival;Epigenomes;2024-08-21

2. Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing;Frontiers in Immunology;2024-06-06

3. Genome-wide methylation profiling of Peripheral T-cell lymphomas identifies TRIP13 as a critical driver of tumor proliferation and survival;2024-02-29

4. Spatial organization and early signaling of the B-cell receptor in CLL;Frontiers in Immunology;2022-08-09

5. Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery;Expert Opinion on Drug Discovery;2021-06-11